RxDoctor Payments Data

Dov Linzer, MD

Cardiovascular Disease · Pembroke Pines, FLNPI 1659312684

Payments from drug & device makers

$3,212in general payments, 2019–2025

Across 178 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$691
  • Amgen$576
  • Pfizer$311
  • Amarin Pharma, Inc.$216
  • Johnson & Johnson$205
  • Cvrx, Inc.$178
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,17099%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,212 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$132,678
Medicare patients
700
Services billed
1,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$157,235
EntrestoSacubitril/Valsartan59$68,328
XareltoRivaroxaban45$48,469
Repatha SureclickEvolocumab19$29,937
BrilintaTicagrelor14$16,152
FarxigaDapagliflozin Propanediol20$11,697
Rosuvastatin Calcium536$7,348
Ezetimibe244$5,870
Metoprolol Succinate409$5,391
Nifedipine ErNifedipine108$3,183
Nebivolol Hcl40$2,959
Losartan Potassium253$2,809
Fenofibrate98$2,480
Atorvastatin Calcium235$2,053
Amlodipine Besylate304$1,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$311$157,235129 claims
NovartisEntresto$691$68,32859 claims
Johnson & JohnsonXarelto$205$48,46945 claims
AstraZenecaBrilinta, Farxiga$65$27,84834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →